Anteris Technologies Global Corp.
AVRHealthcareNASDAQMedical Instruments & Supplies · Last scanned Jun 3, 2026
Scan Results
Daily timeframePart of the healthcare sector, Anteris Technologies Global Corp. (AVR) is listed under Medical Instruments & Supplies. The company carries a $904.3M market cap, placing it firmly in the small-cap category. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve.
Market Cap
$904.3M
Beta
0.59
P/E (TTM)
—
P/E (Fwd)
-9.48
EPS (TTM)
$-2.22
EPS (Fwd)
$-0.98
ROE
-59.2%
ROA
-34.0%
Cash
$282.7M
Total Debt
$3.7M
Free CF
-$52.7M
52W Change
96.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $282.7M in cash comfortably exceeding the $3.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$52.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -59.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $5.8M (2021) to $2.7M (2023), a 53% decline worth watching.
AVR's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AVR.